MX2023003725A - Pharmaceutical compositions and methods for prevention and/or treatment of inflammation. - Google Patents

Pharmaceutical compositions and methods for prevention and/or treatment of inflammation.

Info

Publication number
MX2023003725A
MX2023003725A MX2023003725A MX2023003725A MX2023003725A MX 2023003725 A MX2023003725 A MX 2023003725A MX 2023003725 A MX2023003725 A MX 2023003725A MX 2023003725 A MX2023003725 A MX 2023003725A MX 2023003725 A MX2023003725 A MX 2023003725A
Authority
MX
Mexico
Prior art keywords
treatment
inflammation
prevention
methods
pharmaceutical compositions
Prior art date
Application number
MX2023003725A
Other languages
Spanish (es)
Inventor
Peter Lange
Michael A Volk
Fatih M Uckun
Brian D Denomme
Wyk Hendrick Johanness Petrus Van
Original Assignee
Reven Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reven Pharmaceuticals Inc filed Critical Reven Pharmaceuticals Inc
Publication of MX2023003725A publication Critical patent/MX2023003725A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A61K31/51—Thiamines, e.g. vitamin B1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/34—Copper; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

The disclosure relates to pharmaceutical compositions and methods for the prevention and/or treatment of inflammation, disease, and disorders. The treatment may include treatment of COVID-19.
MX2023003725A 2020-09-30 2021-09-30 Pharmaceutical compositions and methods for prevention and/or treatment of inflammation. MX2023003725A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063085745P 2020-09-30 2020-09-30
PCT/US2021/052884 WO2022072637A1 (en) 2020-09-30 2021-09-30 Pharmaceutical compositions and methods for prevention and/or treatment of inflammation

Publications (1)

Publication Number Publication Date
MX2023003725A true MX2023003725A (en) 2023-06-28

Family

ID=80823058

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023003725A MX2023003725A (en) 2020-09-30 2021-09-30 Pharmaceutical compositions and methods for prevention and/or treatment of inflammation.

Country Status (9)

Country Link
US (1) US20220096538A1 (en)
EP (1) EP4221516A1 (en)
JP (1) JP2023545404A (en)
CN (1) CN116568276A (en)
AU (1) AU2021351504A1 (en)
CA (1) CA3194304A1 (en)
IL (1) IL301794A (en)
MX (1) MX2023003725A (en)
WO (1) WO2022072637A1 (en)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0212405D0 (en) * 2002-05-29 2002-07-10 Insignion Holdings Ltd Composition and its therapeutic use
US20110044945A1 (en) * 2007-02-08 2011-02-24 Rappaport Family Institute For Research In The Medical Sciences Agents for the treatment of multiple sclerosis and methods of using same
BR112013001594A2 (en) * 2010-07-22 2016-05-17 Reven Pharmaceuticals Inc methods of treating or ameliorating disease and improving performance comprising the use of a stabilized magnetic dipole solution
US10729735B1 (en) * 2016-09-14 2020-08-04 Phoenix Biotechnology, Inc. Method and compostitions for treating coronavirus infection
EA202091396A1 (en) * 2017-12-07 2020-09-02 РИВЕН АйПи ХОЛДКО ЭлЭлСи COMPOSITIONS AND METHODS FOR TREATMENT OF METABOLIC CONDITIONS
US20220047646A1 (en) * 2019-02-26 2022-02-17 Pantheryx, Inc. Compositions for management of disorders of the gastrointestinal tract

Also Published As

Publication number Publication date
EP4221516A1 (en) 2023-08-09
CA3194304A1 (en) 2022-04-07
IL301794A (en) 2023-05-01
AU2021351504A1 (en) 2023-05-25
CN116568276A (en) 2023-08-08
JP2023545404A (en) 2023-10-30
AU2021351504A9 (en) 2024-02-08
WO2022072637A1 (en) 2022-04-07
US20220096538A1 (en) 2022-03-31

Similar Documents

Publication Publication Date Title
MX2021009246A (en) Immunomodulators, compositions and methods thereof.
MX2019010848A (en) Compositions and methods for treating cancer.
PH12020551425A1 (en) Rimegepant for cgrp related disorders
MX2022016415A (en) Glycolate oxidase inhibitors for the treatment of disease.
MX2021010888A (en) Heteroaromatic and heterobicyclic aromatic derivatives for the treatment of ferroptosis-related disorders.
NZ754764A (en) Pyrimidine tricyclic enone derivatives for inhibition of rorγ and other uses
MX2023003678A (en) Hsd17b13 inhibitors and uses thereof.
MX2023009685A (en) Tyk2 inhibitors and uses thereof.
MX2023003677A (en) Hsd17b13 inhibitors and uses thereof.
MX2020007586A (en) Process of making somatostatin modulators.
PH12021550872A1 (en) Therapeutic compounds
CR20220215A (en) Heteroaryl-biphenyl amides for the treatment of pd-l1 diseases
MX2020012107A (en) Compositions and methods for treating cancer.
MX2022009762A (en) P2x3 modulators.
MX2023009723A (en) Tyk2 inhibitors and uses thereof.
MX2023009682A (en) Tyk2 inhibitors and uses thereof.
EP4282414A3 (en) Modified release tablet formulations containing phosphodiesterase inhibitors
MX2022014924A (en) Il-17a modulators.
MX2023010711A (en) Phenalkylamines and methods of making and using the same.
MX2022000712A (en) Nlrp3 modulators.
MX2023001296A (en) Compositions and methods for treating diseases and disorders.
PH12020551179A1 (en) Methods for treating mitochondrial disorder
MX2023003675A (en) Hsd17b13 inhibitors and uses thereof.
WO2020068950A8 (en) Hdac1,2 inhibitors
WO2015048188A3 (en) Modified fibroblast growth factors for the treatment of ocular disorders